Department of Human Pathology, School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan.
Department of Diagnostic Pathology, Faculty of Medicine, University of Toyama, Toyama, Japan.
Virchows Arch. 2022 Dec;481(6):865-876. doi: 10.1007/s00428-022-03415-3. Epub 2022 Sep 24.
Intraductal oncocytic papillary neoplasms (IOPNs) of the pancreatobiliary system are tumors comprising oncocytic cells, in which three types of fusion genes involving -PRKACA/-PRKACB were recently identified. IOPNs infrequently combine with other histological subtypes of pancreatic intraductal papillary mucinous neoplasms (IPMNs) and intraductal papillary neoplasms of the bile duct (IPNBs). This study aimed to confirm the sensitivity/specificity of the fusion genes for IOPNs and to examine their significance in other oncocytic lesions. An RT-PCR, followed by DNA sequencing, was undertaken to examine the fusions in 18 histologically diagnosed IOPNs, including four combined IOPNs. Moreover, in two IOPN cases, invasive carcinomatous lesions were separately examined on their fusion status. Oncocytic thyroidal (n = 10), renal (n = 10), and salivary gland (n = 3) lesions and IPMNs (n = 9)/IPNBs (n = 4) with focal oncocytic changes were examined as controls. Fluorescence in situ hybridization using PRKACA break-apart probes was conducted for the combined IOPN cases. Target sequencing of KRAS exon2/3 and GNAS exon 8/9 was performed for IOPN cases. Fusions were detected in all IOPN cases including invasive lesions/none of the control cases. The fusion event was confirmed also in non-IOPN component in one of the four combined cases. Regarding mutation events, 5.6%/0% of IOPNs were KRAS-mt/GNAS-mt, respectively, and both components of combined IOPNs were all KRAS-wt/GNAS-wt. In conclusion, our study confirmed the sensitivity and specificity of these fusions for IOPNs. Here, we analyzed the roles of these fusion genes in combined IOPNs, proposing the possibility of IOPN development via IPMNs/IPNBs. Further studies with more combined cases are warranted.
胰腺胆道系统的导管内嗜酸细胞性乳头状肿瘤(IOPN)是由嗜酸细胞组成的肿瘤,最近发现涉及-PRKACA/-PRKACB 的三种融合基因。IOPN 很少与其他组织学亚型的胰腺导管内乳头状黏液性肿瘤(IPMN)和胆管内乳头状肿瘤(IPNB)合并。本研究旨在确认融合基因对 IOPN 的敏感性/特异性,并研究其在其他嗜酸细胞病变中的意义。采用 RT-PCR 后行 DNA 测序,对 18 例组织学诊断为 IOPN 的患者(包括 4 例合并 IOPN)进行融合基因检测。此外,在 2 例 IOPN 病例中,分别对侵袭性癌性病变进行融合状态检测。作为对照,检测了 10 例嗜酸细胞性甲状腺(n=10)、肾(n=10)和唾液腺(n=3)病变,以及伴有局灶嗜酸细胞改变的 IPMN(n=9)/IPNB(n=4)。对合并的 IOPN 病例进行了 PRKACA 断裂探针的荧光原位杂交。对 IOPN 病例进行了 KRAS 外显子 2/3 和 GNAS 外显子 8/9 的靶向测序。所有 IOPN 病例均检测到融合,而无一例对照病例。在 4 例合并病例中的 1 例,还在非 IOPN 成分中证实了融合事件。关于突变事件,分别有 5.6%/0%的 IOPN 为 KRAS-mt/GNAS-mt,而合并的 IOPN 的两个成分均为 KRAS-wt/GNAS-wt。总之,本研究证实了这些融合基因对 IOPN 的敏感性和特异性。在此,我们分析了这些融合基因在合并 IOPN 中的作用,提出了 IOPN 通过 IPMN/IPNB 发展的可能性。需要进一步的研究来分析更多的合并病例。